The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Real-world outcomes of bispecific antibodies in R/R follicular lymphoma
Jessica Allen, MD, Huntsman Cancer Institute, Salt Lake City, UT, discusses a multicenter retrospective study evaluating the real-world efficacy and safety of bispecific antibodies in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated in the Collaborative United States Bispecifics Consortium (CUBIC). Patient outcomes were highly encouraging in this heavily pretreated population, with response rates exceeding those reported in clinical trials. Additionally, the safety profile was favorable, with low rates of toxicities. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Our study looked at patients across 11 academic U.S. centers. We had 99 patients with relapsed/refractory follicular lymphoma treated with bispecific antibodies in the standard of care setting. And our goal is to see if they were as efficacious and safe as they seem to be in the clinical trials in a real-world population. And the answer really seems to be yes. For context, our population included older patients...
Our study looked at patients across 11 academic U.S. centers. We had 99 patients with relapsed/refractory follicular lymphoma treated with bispecific antibodies in the standard of care setting. And our goal is to see if they were as efficacious and safe as they seem to be in the clinical trials in a real-world population. And the answer really seems to be yes. For context, our population included older patients. The median age was 68 years. Over 60% of patients were 65 years or older, and 12% were 80 years or older. Half had progression of disease within the first 24 months of initial therapy. About half had high-risk FLIPI score. Most patients had advanced stage disease. So it was a very high-risk, heavily pretreated group as well. The median prior line of therapy was 3, but it went up to 14 lines of therapy.
And despite all of this, we still had really impressive response rates. There was an overall response rate of 87%, a complete response rate of 72%, a 12-month PFS of 72%, and then a 12-month OS of 94%. So actually, the response rates were even better than what the trials had shown, and the survival times were similar. And for context on the survival times, we had about a 17-month median follow-up. As far as safety goes, things were also quite impressive. Only about a third of patients had cytokine release syndrome (CRS), and there were no CRS events greater than grade 2, so no patients needed to be in the ICU. There were no deaths due to CRS. Only 3% of patients had immune cell-associated neurotoxicity syndrome (ICANS) and none greater than grade one. And then about a third of patients had infections, no deaths due to infections. So to conclude all of that, I think we’ve shown, or at least added to evidence, that bispecific antibodies really are safe and effective in the real world setting in patients with relapsed follicular lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
